<DOC>
	<DOCNO>NCT00856284</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness add alogliptin , daily ( QD ) , compare glipizide metformin diabetic patient .</brief_summary>
	<brief_title>Efficacy Safety Alogliptin Plus Metformin Compared Glipizide Plus Metformin Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>For patient diagnose type 2 diabetes mellitus , metformin usual first-line therapy addition diet control exercise . For patient inadequate glycemic control metformin monotherapy experience serious side effect metformin , sulfonylurea popular choice second-line oral antidiabetic treatment . Alogliptin dipeptidyl peptidase-4 inhibitor currently develop Takeda use patient type 2 diabetes mellitus . This study design explore durability efficacy safety alogliptin compare glipizide type 2 diabetes mellitus patient whose blood sugar level inadequately control metformin therapy . The duration study approximately 2 year .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Glipizide</mesh_term>
	<criteria>Has diagnosis type 2 diabetes mellitus . Must meet one follow : Has inadequately control stable daily dose ≥1500 mg ( document maximum tolerate dose ) metformin least 2 month prior Screening . Has inadequately control ( define glycosylated hemoglobin 7.5 10 % , inclusive ) metformin &lt; 1500 mg without document maximum tolerate dose . No treatment antidiabetic agent metformin within 2 month prior Screening ( Schedule A ) /PreScreening ( Schedule B ) . Has body mass index within 23 kg/m^2 45 kg/m^2 unless patient Asian Asian descent , allowable body mass index ≥ 20 kg/m^2 ≤ 35 kg/m^2 , inclusive . Has fast Cpeptide concentration least 0.8 ng . If regularly use nonexcluded medication , must stable dose least 4 week prior Screening/Prescreening . Females childbearing potential sexually active must agree use adequate contraception , neither pregnant , lactate intend donate ovum Screening throughout duration study . Must able willing monitor blood glucose concentration home monitor , comply protocol requirement include schedule clinic appointment . Systolic blood pressure great equal 150 mmHg and/or diastolic pressure great equal 90 . Hemoglobin le equal 12 g/dL male less equal 10 g/dL female Screening Visit . Alanine aminotransferase great equal 2.5 time upper limit normal Screening Visit . Serum creatinine great equal 1.5 mg/dL male 1.4 female , calculate creatinine clearance le 60 L/min . Males intend impregnate others donate sperm , within 1 month participate study . A history cancer squamous basal cell carcinoma skin full remission least 5 year . A history laser treatment diabetic retinopathy within 6 month screen . Treated diabetic gastric paresis , gastric banding , gastric bypass . New York Heart Association Class III IV heart failure . History coronary angioplasty , coronary stent placement , coronary bypass surgery , myocardial infarction , stroke transient ischemic attack within 3 month prior screen . Known history human immunodeficiency virus , hepatitis B C. Alcohol substance abuse within 2 year prior screen . Is required take intend continue take disallowed medication , prescription medication , herbal treatment overthe counter medication may interfere evaluation study medication , include : Any investigational drug within 30 day Any investigational diabetic drug within 3 month Any antidiabetic drug dipeptidyl peptidase4 inhibitor glucagonlike peptide1 mimetics class within 90 day prior Screening metformin Prior treatment alogliptin . Weightloss drug Oral systemically inject glucocorticoid A hypersensitivity allergy anaphylactic reaction dipeptidyl peptidase4 drug , metformin glipizide . Has document history concurrent sign significant thyroid disease ( eg , autoimmune thyroid diseases Graves disease Hashimoto thyroiditis active thyroid nodule ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Hyperinsulinism</keyword>
	<keyword>Hyperglycemia</keyword>
	<keyword>Glucose Intolerance</keyword>
</DOC>